• Register
  • Login

Iranian Journal of Pharmaceutical Sciences

  • Home
  • Journal Info
    • About the Journal
    • Aims and Scope
    • Editorial Team
    • Indexing & Abstracting
    • Privacy Statement
    • Contact us
  • Issues
    • Current
    • Archives
  • New Submissions
  • Author Guidelines
  • Policies & Process
    • Peer Review
    • Publication Ethics
    • Open Access Policy
    • Plagiarism
    • Retraction Policies
    • Archiving
  • Ethical Considration
Advanced Search
  1. Home
  2. Archives
  3. Vol. 9 No. 2 (2013): IJPS_Volume 9_Issue 2 (2013)
  4. Research/Original Articles

Vol. 9 No. 2 (2013)

Farvardin 2013

Implications of Pharmacoeconomics for Iran National Health System Implications of Pharmacoeconomics for Iran National Health System

  • Abdol Majid Cheraghali

Iranian Journal of Pharmaceutical Sciences, Vol. 9 No. 2 (2013), 1 Farvardin 2013 , Page 81-85
https://doi.org/10.22037/ijps.v9.40905

  • View Article
  • Download
  • Cite
  • References
  • Statastics
  • Share

Abstract

Like many other developing countries pharmacoeconomics and outcome research and its applications in national health system is a new but promising filed in Iran. Although decision makers of Iran national health system decided to use pharmacoeconomics in the decision making approach several hurdles including lack of reliable national data, lack of expertise and local experience are the main challenges in this filed. Recent activities in training graduate students in the field of health technology assessment in the universities could play a major role in advancing this field in Iran.

Keywords:
  • Pharmacoeconomics
  • Pharmaceutical Industry
  • Health system
  • Iran
  • IJPS_Volume 9_Issue 2_Pages 81-85

How to Cite

Abdol Majid Cheraghali. (2013). Implications of Pharmacoeconomics for Iran National Health System: Implications of Pharmacoeconomics for Iran National Health System. Iranian Journal of Pharmaceutical Sciences, 9(2), 81–85. https://doi.org/10.22037/ijps.v9.40905
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

References

[1] Merdad R, Health system in Iran, JMAJ (2009) 52:69-73.
[2] Ibrahimipour H, MR Maleki, R Brown, M Gohari, I Karimi and R Dehnavieh, A qualitative study of the difficulties in reaching sustainable universal health insurance coverage in Iran, Health Policy Plan (2011) 26: 485-495.
[3] Cheraghali AM, Pharmacoeconomics: an effective tool for prioritization in Iran Health care System, Iran.J. Pharm. Res ( 2008)7:89-91.
[4] Davari M, Pharmacoeconomics; An appropriate tool for policy makers or just a new field of research in Iran? Iran. J. Pharm. Res ( 2012) 11: 1-2.
[5] Baber Z and Scahill S, Is there a role for pharmacoeconomics in developing countries? Pharmacoeconomics (2010 ) 28: 1069-74.
[6]http://www.ispor.org/regional_chapters/Iran/ documents/ISPOR-Iran-Chapter-Constitution.pdf
[7] Cheraghali AM, Iran pharmaceutical market, Iran. J. Pharm. Res (2006) 1: 1-7.
[8] Cheraghali AM, Current status of biopharmaceutical in the Iran pharmaceutical market, GaBi Journal ( 2013) 2: 26-29.
[9] Miller P, Role of pharmacoeconomics analysis in R&D decision making, when, where, how? Pharmacoeconomics (2005) 23: 1-12.
  • Abstract Viewed: 302 times
  • IJPS_Volume 9_Issue 2_Pages 81-85 Downloaded: 238 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram

Developed By

Open Journal Systems

Information

  • For Readers
  • For Authors
  • For Librarians
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact

Creative Commons License
This journal (and its contents) is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Print ISSN: 1735-2444

Online ISSN: 2252-0457

Powered by OJSPlus